Resverlogix Announces Participation in Upcoming Conferences
November 02 2017 - 8:00AM
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is
pleased to announce the Company’s participation in the following
upcoming industry conferences.
•
American Society of Nephrology – ASN 2017 Annual Meeting |
Location: |
New Orleans, LA. |
Date: |
November 3rd,
2017 |
Poster 1: |
“Analysis of the Plasma
Proteome Reveals Dysregulation of Molecular Pathways in Patients
with Stage 4 Chronic Kidney Disease” |
Presentation Time: |
10:00am - 12:00pm
CT |
|
|
Date: |
November 4th,
2017 |
Poster 2: |
“Apabetalone (RVX-208)
Impacts Key Markers and Pathways Associated with Chronic Kidney
Disease in Patients with Severe Renal Impairment” |
Presentation Time: |
10:00am - 12:00pm
CT |
Meeting Link: |
LINK |
•
BIO-Europe 2017 |
Location: |
Berlin, Germany. |
Date: |
November 7th, 2017 |
Presentation Time: |
4:45pm CEST |
Presenting: |
Mr. Donald McCaffrey,
President and Chief Executive Officer |
Conference Link: |
LINK |
•
American Heart Association – AHA Scientific Sessions 2017 |
Location: |
Anaheim, CA |
Date: |
November 13th,
2017 |
Poster: |
“Apabetalone
Downregulates Factors That Promote Vascular Calcification and
Contribute to Cardiovascular Events” |
Presentation Time: |
10:30am PT |
Meeting Link: |
LINK |
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET
inhibitor selective for the second bromodomain (BD2) within the BET
protein called BRD4. This selective inhibition of apabetalone on
BD2 produces a specific set of biological effects with potentially
important benefits for patients with high-risk cardiovascular
disease (CVD), diabetes mellitus (DM), chronic kidney disease,
end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is the only selective BET bromodomain
inhibitor in human clinical trials. Apabetalone is currently being
studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL), and is
expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up
to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
For further information please
visit www.resverlogix.com.
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or
on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations Email:
ir@resverlogix.com Phone: 403-254-9252
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024